Nicholas Saraceno, Senior Editor

Analysis determines the suggested value of medications for diabetes if they were closer to production costs.

Syneos Health's Kim Plesnarski uncovers the key issues that customers are currently trying to address, including the retail shift from small-molecule products to biologics.

Cross-sectional study explores the impact of this monumental Supreme Court ruling.

Qualitative study breaks down challenges and priorities of the Medicare Shared Savings Program, as noted by affordable care organizations.

Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency.

Five of the company’s vaccines are currently in Phase III.

A study investigates how a New Mexico law can impact patients’ out-of-pocket costs surrounding mental health and substance use disorder medications.

The new option will help patients receive life-saving medications at an even quicker rate.

A study of patients with the long-term conditions who are required to switch to high-deductible health plans could potentially be more likely to experience diabetes complications than those who stay in standard insurance plans.

The organizations conducted an in-depth study of the program over the course of two years, publishing a white paper on the findings.

The purpose for the deal, the CDMO says, is to meet the demand for commercial mammalian contract manufacturing.

A multiple myeloma survivor shares his story, including how patient assistance made a positive impact.

Presentation discusses the evolution of the patient assistance landscape, while presenting ways to collaborate.

Presentation offers insight on this aforementioned model that assists retail and specialty-lite brands.

Fireside chat uncovers ways to leverage this technology in order to boost medication adherence, engagement, and outcomes.

Panel discusses PAN Foundation’s inaugural “State of Patient Access” report, and dives deep into patient challenges.

Conference’s opening session addresses the evolving landscape of healthcare coverage and accessibility.

This financial toxicity is quite prominent, but what can be done to remedy treatment costs?

Under the group purchasing agreement, the serialization business will be the sole provider of DSCSA services for Premier’s 4,300-plus hospital and health system network.

Steven H. Collis, who currently holds the position, will transition to executive chair of the board.

The Asia-Pacific location is expected to provide serialization solutions for counterfeit medication entering the pharma supply chain.

A qualitative study explores how these drugs are impacting these patients’ lives, while digging deeper into the possibility of deprescribing, with insight from primary care physicians.

The company’s twice-daily, branded ruxolitinib cream 1.5% presents a significant reduction in abscess and inflammatory nodule (AN) count for the treatment of Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa.

A USC study discovers that an increasing share of both generic and brand-name meds are being excluded from approval.

With out-of-pocket healthcare costs resulting in financial issues for patients, a cross-sectional study closely examines whether they are linked to more premature deaths.

A proposed Senate bill is intended to protect citizens’ private health and genetic information.

The contributions consist of multiple investments that aim to boost pandemic preparedness and overall public health protection.

The CDMO’s multi-million-dollar expansion project features commercial manufacturing suites and peptide manufacturing plants.

The CDC urges healthcare providers to preserve their current supply.

The pTau217 antibody helps pinpoint pathological changes related to the disease.